Bimzelx: payments to doctors
Payments that named Bimzelx as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $26.8M
- Providers
- 22,270
- Transactions
- 203,498
- Average per transaction
- $132
The per-transaction average — $132 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 22,270 providers the average total is $1,203, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| UCB, Inc. | $26,231,088 | 97.9% |
| UCB SA | $548,707 | 2.0% |
| UCB Biosciences Inc. | $2,000 | 0.0% |